Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 13/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.46 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12048193 | 0.91 | FDPS (0.46) | FDPSGGPS1BTN3A1PDE3APABPC1 | |
| SCHEMBL12060628 | 0.83 | GGPS1 (0.62) | FDPSGGPS1 | |
| SCHEMBL12060615 | 0.77 | FDPS (0.47) | FDPSGGPS1 | |
| SCHEMBL12048185 | 0.75 | GGPS1 (0.57) | FDPSGGPS1 | |
| Hydrochloric Acid SCHEMBL3780200 | 0.73 | PABPC1 (0.40) | FDPSGGPS1PABPC1APOBEC3AEIF4H | |
| Hydrochloric Acid SCHEMBL193627 | 0.73 | PABPC1 (0.40) | FDPSGGPS1PABPC1APOBEC3AEIF4H | |
| SCHEMBL5672430 | 0.73 | FDPS (0.47) | FDPSGGPS1PABPC1APOBEC3AEIF4H | |
| SCHEMBL12931025 | 0.72 | MAPT (0.55) | PABPC1APOBEC3AEIF4HAPOBEC3GLMNA | |
| Bromide SCHEMBL5586402 | 0.72 | PABPC1 (0.39) | FDPSPABPC1APOBEC3AEIF4HAPOBEC3G | |
| SCHEMBL12060368 | 0.72 | FDPS (0.46) | FDPSGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071573-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100316676-A1 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-12-16 | — | — | US | disclosed |
| US-7745422-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316676-A1 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases | FDPS, GGPS1, MVD | FDPS 1/4885GGPS1 2/4885BTN3A1 513/4885 |
| US-20080318906-A1 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES | FDPS, GGPS1, MVD | FDPS 1/4885GGPS1 2/4885BTN3A1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.